QC
CSTL icon

Quadrature Capital’s Castle Biosciences CSTL Stock Holding History

Quadrature Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$243K Buy
+10,175
New +$227K ﹤0.01% 1290

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrature Capital's CSTL Position: Q2 2026 in Review

Quadrature Capital opened a new position in Castle Biosciences (CSTL) in Q2 2026: 10,175 shares worth $243K. The stake represents ﹤0.01% of the portfolio and ranks #1290 among its holdings.

177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Quadrature Capital held 10,175 shares of Castle Biosciences worth $243K as of Q2 2026.
  • Castle Biosciences was a new Quadrature Capital position in Q2 2026.
  • Castle Biosciences made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1290 holding.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.